Member Info for JESK

No. They must think the gin market is saturated, no pun intended. Hoping these drinks go down a storm this summer.

A good article. However, unfortunately, not mention of Avacta.

https://www.theguardian.com/commentisfree/2021/apr/19/lateral-flow-tests-uk-covid

Interesting article in the Yorkshire Post. According to the article Avacta are in discussions with distributors in 25 EU markets. Bring on the volumes.

An interesting article in the Yorkshire Post. According to the article Avacta are in discussion with distributors in 25 EU markets.

https://www.yorkshirepost.co.uk/business/yorkshire-covid-test-will-be-the-most-sensitive-lateral-flow-test-available-3209746

The new botanical vodkas look great. Love the packaging. Looks like a great summer drink.

https://www.distil.uk.com/our-brands/#trove

Wow that was quick. Just about to add that.

As a matter of interest Doggo, what are your stop losses set at? If this tanks, will you be guaranteed your stop loss price? Thanks

Finally found out how many tickets were sold for the Liam Gallagher gig - 35,000. Not a bad number. Over half a million quid generated. Do feel with 'bigger' names and real global stars the numbers could be substantially bigger. Patience is certainly required with this share. Let's hope the new app is the real deal and there is a massive campaign to sell the new app.

Reflecting on the timing of the investors presentation and end of year results, it would be nonsensical to present to existing and potentially new investors on Thursday if the clinical results for the LFT were not very good. The end of year results will be no real surprise as most of the information was covered in the business update in February. Dr Smith is not stupid and the new PR Agency would not allow a presentation to go ahead in an atmosphere of failure. The only logical conclusion as far as I can gather is there has been a slight delay, but all will be revealed early next week with a massive fanfare. Good luck to all long term shareholders.

New tropical rum launching on 18th April. Hopefully Trove botanical vodkas will also be launched soon. A trading update next week. A lot to look forward to here.

No he did not. I have watched the interview twice and that is a complete falsehood.

Held this share for many years now. Bought in first at about 74p when I read about the 'viagra' type condoms, think they were called 'Blue Diamond.' Watched the share price steadily decline, but was always hopeful. Averaged down over the years to about 30p. Then about three years ago the share rocketed to over 90p. I thought the tide had turned and the data from patient use would pass easily. Then saw the share price gradually fall to about 7p. The unctuous toad Barder taking placing after placing and talking deals with 'punchy' numbers which never materialized. However, I kept my shares. Hate selling at a loss and suffered in silence. However, yesterday's news was the real deal. Patience has been rewarded and yesterday's rise was only the start.

Agree Doze, but Dr Smith is such an articulate speaker, I want to hear him fully explain all the opportunities available to Avacta, rather than Paul butting in and wasting valuable time.

Agree about Paul Hill. He is extremely enthusiastic, but too over exuberant at times. The best interviewers allow the subject to do the vast majority of the talking. The star of the interview should have been Dr Smith, but Paul was determined to hold centre stage far too much. I mentioned this on Twitter and to be fair Paul thanked me for my observation and feedback. Hopefully in the next interview Dr Smith will take centre stage.

Wow. Aim guru Myles McNulty has taken a position here. His research is meticulous and he is rarely wrong about a share.

Werfen operate in over 30 countries. With distributors in over 100 territories. That is big.

No problem. This is from the Adeptrix tie up with Bruker in January.

The current inventory of BAMS reagents have been configured for protein analysis in the fields of neurology, oncology and epigenetics. Over 30 assays are planned for release in Q1 2021.

Hopefully Avacta will be involved with a number of those reagents. This as you said could prove to be a lucrative endeavour.

Paul has tweeted from PHM Capital saying that he is hoping to set up another interview with Dr Smith early next week. He will be discussing 3rd party royalty opportunities and hopefully coincide with a nice, juicy contract from Bruker for Bams.

Red leg rum at number 8 in the spirits best sellers and number 1 on the rum best sellers. It is only 15 quid, but they must be shifting some units. Hopefully the new botanical vodka line will be out soon. If it becomes as successful as the Red leg brand this company will be really going places.

https://www.amazon.co.uk/Best-Sellers-Grocery-Beer-Wine-Spirits/zgbs/grocery/358583031/ref=zg_bs_nav_grocery_1_grocery

Maybe news on Bams this week? Dr Smith said between two and three weeks and we are moving into the second week since his announcement. A nice, juicy contract with Bruker would be a perfect entree to the roll out of the LFT and also another confirmation of the power of affirmers.